^
    Back
    Association details:
    Biomarker:KIT exon 9 mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Gastric Cancer
    Title:

    Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

    Published date:
    01/20/2022
    Excerpt:
    In archived tumor samples, 67% (68/102) had a KIT mutation; 61% (62/102) had primary KIT mutations (exons 9 and 11) and 12% (12/102) had secondary mutations (exons 13, 14, 17, and 18)….Regorafenib showed PFS benefit across all primary and secondary KIT mutational subgroups examined....These data support the results of the GRID trial, and suggest that patients may benefit from regorafenib in the presence of KIT mutations...
    DOI:
    https://doi.org/10.1007/s10120-021-01274-6
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Gastrointest Oncol
    Title:

    Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review

    Excerpt:
    Regorafenib as a third line option has demonstrated some improvement in exon 9 mutated GISTs with benefits similar to that seen in exon 11 mutated tumors
    DOI:
    10.21037/jgo.2016.09.15